NCT04758767View on ClinicalTrials.gov

CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

CID-103

anti-CD38 antibody

Trial Locations (4)

Unknown

CHU de Nantes - Hôpital Hôtel-Dieu, Nantes

CHU Rennes - Pontchaillou, Rennes

Gustave Roussy Cancer Center, Villejuif

Sarah Cannon, London

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT04758767 - CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter